FDANews
FDAnews Drug Daily Bulletin

ANTARES PHARMA SIGNS DEVELOPMENT AGREEMENT WITH COMPANY SPECIALIZING IN CNS PRODUCTS

Dec. 7, 2005

Antares Pharma, Inc. (Amex: AIS -- News) today announced having signed a development agreement with a presently unnamed pharmaceutical company specializing in products for the treatment of central nervous system (CNS) disorders. Under the agreement, Antares will apply its advanced transdermal delivery (ATD(TM)) gel platform to create a new, branded pharmaceutical product. Antares will recognize research and development revenue from this work, which is currently underway. Commercial terms have been agreed upon and will be included in a subsequent license agreement upon successful completion of the initial phase of this program.

Yahoo News (http://biz.yahoo.com/prnews/051206/phtu015.html?.v=38)